Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410837" target="_blank" >RIV/00216208:11130/20:10410837 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/20:10410837

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D5KfEvne-U" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D5KfEvne-U</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-020-0749-5" target="_blank" >10.1038/s41375-020-0749-5</a>

Result language

angličtina

Original language name

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

Original language description

Pediatric patients with relapsed/refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL) have a 2-year overall survival rate with chemoimmunotherapy (CIT) of 15-33%. Rituximab plus ifosfamide, carboplatin, and etoposide (RICE) is widely used in R/R children with NHL and rituximab plus vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone (RVICI) has been used in Europe. In preclinical studies, ibrutinib, a Bruton&apos;s tyrosine kinase inhibitor approved to treat adults with various B-cell malignancies in the United States and the European Union, among other countries [6], inhibited Burkitt lymphoma (BL; the predominant pediatric mature B-NHL) and diffuse large B-cell lymphoma (DLBCL) tumor cell growth, and prolonged survival in BL xenografted mice. We report safety, pharmacokinetics, and preliminary efficacy findings from the run-in stage (part 1; December 2016-December 2018) of an ongoing phase 3 trial (SPARKLE).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia

ISSN

0887-6924

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

8

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

2271-2275

UT code for WoS article

000514261800002

EID of the result in the Scopus database

2-s2.0-85079822301